欧洲重症儿科喘协作:对儿童生物药物的真实数据
Norrice M Liu1, Mariëlle W Pijnenburg2, Antoine Deschildre3
1Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of London, UK.
ERJ open research
|June 24, 2025
概括
现实世界的数据显示,许多患有严重喘的儿童在生物药物上仍然经历了恶化. 在生物疗法之间切换是常见的,这表明持续需要更好的治疗严重的儿科喘.
科学领域:
- 儿科肺病学 儿科肺病学
- 临床免疫学临床免疫学
- 现实世界的证据研究研究.
背景情况:
- 严重的儿科喘缺乏全面的现实世界数据,特别是对于接受生物疗法的儿童.
- 了解这些儿童的特征和治疗结果对于推进护理至关重要.
研究的目的:
- 描述接受生物治疗的严重喘儿童的特征.
- 评估这一群体中的喘控制,严重程度和治疗模式.
主要方法:
- 欧洲严重儿科喘协作组织 (SPACE) 招募了250名患有严重喘的儿童接受生物药物治疗.
- 收集的数据包括人口统计,喘控制 (GINA标准),严重程度指数 (CASI),恶化,肺功能和生活质量.
- 不同生物制剂之间的比较根据年龄,性别和治疗持续时间进行了调整.
主要成果:
- 在儿童中,奥马利祖马布被使用了56.8%,梅波利祖马布被使用了21.6%,杜比卢马布被使用了21.6%.
- 尽管接受了治疗,但有27%的患者患有部分控制的喘,8%患有不受控制的喘 (GINA标准).
- 超过50%的人在过去一年中至少经历过一次恶化,10%的人住院治疗.
结论:
- 大多数服用生物药物的儿童都能够很好地控制症状,但喘发作和控制仍然存在重大挑战.
- 很大一部分患者转换了生物药物,通常是由于没有反应.
- 在严重的儿科喘中,仍然有更有效的治疗方法的明显未满足的需求.
相关概念视频
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:20Asthma: Pathogenesis and Management
618
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
618
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
399
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
399
01:26COPD: Management Using Bronchodilators and Corticosteroids
329
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
329
01:26Asthma-II: Pathophysiology and Classification
2.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
502
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
502